Costs incurred by patients with tuberculosis co-infected with human immunodeficiency virus in Bhavnagar, western India: a sequential explanatory mixed-methods research

被引:2
|
作者
Rupani, Mihir P. [1 ,2 ,3 ]
Vyas, Sheetal [3 ,4 ]
机构
[1] Maharaja Krishnakumarsinhji Bhavnagar Univ, Govt Med Coll Bhavnagar, Dept Community Med, Near ST Bus Stand,Jail Rd, Bhavnagar 364001, Gujarat, India
[2] ICMR Natl Inst Occupat Hlth NIOH, Clin Epidemiol, Div Hlth Sci, Near Raksha Shakti Univ, Ahmadabad 380016, Gujarat, India
[3] Gujarat Univ, Ahmadabad, Gujarat, India
[4] AMC MET Med Coll, Dept Community Med, Ahmadabad 380008, Gujarat, India
关键词
Social protection; Negative financial coping; Collaborative framework; Bidirectional activities; National tuberculosis elimination program; Universal cash transfers; India; HIV;
D O I
10.1186/s12913-022-08647-2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: India reports the highest number of tuberculosis (TB) and second-highest number of the human immunodeficiency virus (HIV) globally. We hypothesize that HIV might increase the existing financial burden of care among patients with TB. We conducted this study to estimate the costs incurred by patients with TB co-infected with HIV and to explore the perspectives of patients as well as program functionaries for reducing the costs. Methods: We conducted a descriptive cross-sectional study among 234 co-infected TB-HIV patients notified in the Bhavnagar region of western India from 2017 to 2020 to estimate the costs incurred, followed by in-depth interviews among program functionaries and patients to explore the solutions for reducing the costs. Costs were estimated in Indian rupees (INR) and expressed as median (interquartile range IQR). The World Health Organization defines catastrophic costs as when the total costs incurred by patients exceed 20% of annual household income. The in-depth interviews were audio-recorded, transcribed, and analyzed as codes grouped into categories. Results: Among the 234 TB-HIV co-infected patients, 78% were male, 18% were sole earners in the family, and their median (IQR) monthly family income was INR 9000 (7500-11,000) [similar to US$ 132 (110-162)]. The total median (IQR) costs incurred for TB were INR 4613 (2541-7429) [similar to US$ 69 (37-109)], which increased to INR 7355 (4337-11,657) [similar to US$ 108 (64-171)] on adding the costs due to HIV. The catastrophic costs at a 20% cut-off of annual household income for TB were 4% (95% CI 2-8%), which increased to 12% (95% CI 8-16%) on adding the costs due to HIV. Strengthening health systems, cash benefits, reducing costs through timely referral, awareness generation, and improvements in caregiving were some of the solutions provided by program functionaries and the patients. Conclusion: We conclude that catastrophic costs due to TB-HIV co-infection were higher than that due to TB alone in our study setting. Bringing care closer to the patients would reduce their costs. Strengthening town-level healthcare facilities for diagnostics as well as treatment might shift the healthcare-seeking of patients from the private sector towards the government and thereby reduce the costs incurred.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Costs incurred by patients with tuberculosis co-infected with human immunodeficiency virus in Bhavnagar, western India: a sequential explanatory mixed-methods research
    Mihir P. Rupani
    Sheetal Vyas
    [J]. BMC Health Services Research, 22
  • [2] A sequential explanatory mixed-methods study on costs incurred by patients with tuberculosis comorbid with diabetes in Bhavnagar, western India
    Rupani, Mihir P.
    Vyas, Sheetal
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01):
  • [3] A sequential explanatory mixed-methods study on costs incurred by patients with tuberculosis comorbid with diabetes in Bhavnagar, western India
    Mihir P. Rupani
    Sheetal Vyas
    [J]. Scientific Reports, 13 (1)
  • [4] Ocular Tuberculosis in Human Immunodeficiency Virus and Systemic Tuberculosis Co-infected Patients
    Jain, Sahil
    Bajgai, Priya
    Kaur, Savleen
    Dogra, Mohit
    Sharma, Aman
    Sharma, Kusum
    Katoch, Deeksha
    Dogra, Mangat R.
    Gupta, Vishali
    Singh, Ramandeep
    [J]. OCULAR IMMUNOLOGY AND INFLAMMATION, 2021, 29 (05) : 1002 - 1006
  • [5] Survival Rates of Human Immunodeficiency Virus and Tuberculosis Co-Infected Patients
    Roshanaei, Ghodratollah
    Ghannad, Masoud Sabouri
    Saatchi, Mohammad
    Khazaei, Salman
    Mirzaei, Mohammad
    [J]. JUNDISHAPUR JOURNAL OF MICROBIOLOGY, 2014, 7 (06)
  • [6] Combination treatment for visceral leishmaniasis patients co-infected with human immunodeficiency virus in India
    Mahajan, R.
    Das, P.
    Isaakidis, P.
    Sunyoto, T.
    Sagili, K. D.
    Lima, M. A.
    Mitra, G.
    Kumar, D.
    Pandey, K.
    Van Geertruyden, J. -P.
    Boelaert, M.
    Burza, S.
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2015, 20 : 207 - 207
  • [7] Combination treatment for visceral leishmaniasis patients co-infected with human immunodeficiency virus in India
    Burza, S.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2016, 45 : 55 - 55
  • [8] Differential Epigenetic Regulation in Uninfected and Tuberculosis-Human Immunodeficiency Virus Co-Infected Patients
    Mamabolo, Katlego
    Wadee, Reubina
    Perner, Yvonne
    Magangane, Pumza
    Duze, Sanelisiwe Thinasonke
    Marimani, Musa
    [J]. MICROORGANISMS, 2024, 12 (05)
  • [9] Survival Rates among Co-infected Patients with Human Immunodeficiency Virus/Tuberculosis in Tehran, Iran
    Roshanaei, Ghodratollah
    Ghannad, Masoud Sabouri
    Poorolajal, Jalal
    Mohraz, Minoo
    Molaeipoor, Leila
    [J]. IRANIAN JOURNAL OF PUBLIC HEALTH, 2017, 46 (08) : 1123 - 1131
  • [10] Clinical description and therapeutic management of tuberculosis in patients co-infected with the human immunodeficiency virus (HIV)
    Delcey, V.
    Mouly, S.
    Zana, D.
    Sellier, P.
    Magnier, J. D.
    Champion, K.
    Bergmann, J. F.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2007, 21 : 54 - 54